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ABSTRACT
During the last two decades, non-alcoholic fatty liver disease (NAFLD) has been a topic in many discussions. 
The major risk factors for NAFLD is metabolic syndrome, which include obesity, insulin resistance and 
hypertension. Beside insulin resistance, oxidative stress has been linked with the disease. 
There is accumulating evidence that intestinal bacterial overgrowth plays an important role in NAFLD 
pathogenesis. Intestinal bacteria influence the progression of NAFLD through endogenous ethanol production 
and cytokine that would eventually induce hepatic oxidative stress. Probiotic intervene pathogenic intestinal 
flora so it is a potential treatment for NAFLD. 
Many animal studies documented the beneficial effect of probiotic in NAFLD. Probiotic reduce hepatic 
inflammation, reduce hepatic steatosis and improve insulin resistance. There is still limited human studies upon 
this topic. However, preliminary result showed potential role of probiotic in NAFLD treatment. Probiotic is 
safe, cheap and widely available therefore it is a promising new approach for NAFLD therapy. Upcoming study 
would hopefully provide firm foundation regarding the use of probiotic for NAFLD on human.
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ABSTRAK
 Dalam dua dekade terakhir, perlemakan hati non-alkoholik (PHNA) merupakan topik hangat yang terus 
diperbincangkan. Faktor risiko dari PHNA meliputi sindrom metabolik, yang meliputi obesitas, resistensi insulin 
dan hipertensi. Disamping resistensi insulin, stres oksidatif juga diduga berhubungan dengan penyakit ini.
 Beberapa penelitian menunjukkan adanya hubungan antara pertumbuhan bakteri usus yang berlebihan 
dengan kejadian PHNA. Bakteri usus mempengaruhi perkembangan PHNA melalui produksi etanol endogen dan 
sitokin yang pada akhirnya menyebabkan stres oksidatif pada hati. Probiotik menghambat flora usus patogen 
sehingga dianggap sebagai terapi potensial untuk PHNA.
 Beberapa penelitian pada objek hewan mendokumentasikan efek yang menguntungkan dari probiotik 
pada PHNA. Probiotik mengurangi inflamasi hati, mengurangi steatosis hati dan memperbaiki resistensi 
insulin. Penelitian pada manusia mengenai topik ini masih sangat terbatas. Namun beberapa hasil penelitian 
pendahuluan menunjukkan peran potensial dari probiotik untuk PHNA. Probiotik adalah terapi yang aman, 
murah dan tersedia secara luas, karena itu merupakan pendekatan yang menjanjikan untuk pengobatan PHNA. 
Penelitian di masa yang akan datang diharapkan dapat menjadi landasan bukti yang kuat untuk memberikan 
rekomendasi penggunaan probiotik untuk PHNA pada manusia.
Kata kunci: PHNA, probiotik, sindrom metabolik
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is 
defined as fat accumulation in the liver exceeding 
5% to 10% by weight, but is estimated practically as 
the percentage of fat-laden hepatocytes observed by 
light microscopy.1 The histologic finding of NAFLD 
encompasses a various degree of inflammation and 
fibrosis. It is similar to that of alcoholic liver disease but 
in the absence of significant alcohol intake. If the liver 
damage continues, it may progress to liver cirrhosis or 
even hepatocellular carcinoma.2,3,4
Certain metabolic risk factors have been strongly 
linked to NAFLD.The association between obesity, 
diabetes mellitus (insulin resistance) and dislipidemia 
with NAFLD has been well documented.5 NAFLD 
affects 10% to 24% of the general population and the 
number increases up to 74% in obese population.6 
Besides insulin resistance and oxidative stress, 
intestinal flora is thought to cause NAFLD. Although 
the exact mechanism remains obscure, small intestinal 
bacterial overgrowth (SIBO) is postulated to induce 
inflammation through the production of cytokine.7
Therapy for NAFLD has been a field of active 
research. There were multiple agents that were 
proved to be beneficial when given to NAFLD 
patients. These agents targeted certain process in the 
pathogenesis of NAFLD. Insulin sensitizer (metformin, 
thiazolidinediones), vitamin E, betaine, ursodeoxycholic 
acid are some agents that have been studied. Besides 
improving the liver transaminase enzymes profile, some 
of these agents even have the capability of improving 
the stage of fibrosis.However there is still no proven 
effective therapy for NAFLD to date.3,8,9,10
As mentioned briefly in previous paragraph, 
pathogenic intestinal flora is one potential culprit of 
NAFLD progression. Probiotics seems a promising 
therapy for NAFLD treatment through the enhancement 
of commensal intestinal flora. Probiotics’ beneficial 
effect has been widely accepted for the management 
of diarrheal disease. However, evidence on the role 
of probiotics in NAFLD is still limited.11 This review 
would provide evidence based information regarding 
the role of probiotic in NAFLD.
THE PATHOGENESIS OF NAFLD
The specific etiology of NAFLD remains an 
unresolved question. However “multiple hits” has 
been the leading theory in the pathogenesis of NAFLD. 
According to this theory, the initial insults (hits), in 
this case insulin resistance leads to hepatic steatosis. 
The first hit made liver cells vulnerable to the second 
insults, which is oxidative stress. The latter eventually 
kills hepatocytes, promotes the accumulation of 
inflammatory cells and further worsen the condition 
which contribute to the occurence of non-alcoholic 
steatohepatitis (NASH). After years of chronic hepatic 
inflammation, some NASH patients develop further 
fibrogenic response  and could progress to cirrhosis.3,7
The First Hit: Insulin Resistance
A combination of genetic and environment factors 
contribute to insulin resistance. Insulin resistance plays 
a central role in the pathogenesis of NAFLD. Insulin 
resistance causes multiple lipid metabolism disorders, 
which include the accumulation of triglycerides in 
hepatocytes as a result of more fatty acids being 
synthesized, more free fatty acids being delivered 
to the liver, less fatty acids being degraded, and less 
triglycerides being released from the liver.7
Excessive amount of free fatty acids may 
be deleterious for the liver through a variety of 
mechanism, including de novo synthesis of ceramides, 
which may cause apoptosis, further contributes to 
insulin resistance by interfering with intracellular 
phosphorylation process and lipid perodixation. 
Chronic hyperinsulinemia also promotes hepatic 
lipogenesis through upregulation of lipogenic 
transcription factors and activate profibrotic cytokines 
such as connective tissue growth factor, which finally 
contribute to liver fibrosis.5,7 
The Second Hit: Oxidative Stress
Mitochondrial dysfunction appears to play a critical 
role in the second hit. There are many etiologies of 
oxidative stress, some of which are oxidation of fatty 
acids and iron load. Fatty acids could induce the 
progression from simple steatosis to steatohepatitis 
through oxidative stress production. TNF-α also 
contributes to the second hit in NASH pathogenesis 
through its effect on mitochondrial radical formation 
which would finally promote cell death.12,13 Intestinal 
flora also plays an important role in cytokine 
production, as will be further explained.14
Hepatic oxidative stress would activate IKB 
Kinase β (IKKβ). IKKβ activation would  result in 
the phosphorylation of insulin receptor substrate 
(IRS)-1, thereby causing disruption of insulin-related 
intracellular signaling and would ultimately result in 
insulin resistance. As can be seen, although there are 
two distinct “hits” in the pathogenesis of NAFLD, 
there are some  overlaps along the process (Figure 1).7
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THE ROLE OF INTESTINAL BACTERIA 
OVERGROWTH IN NAFLD
As a matter of fact, the association between gut 
flora and liver disease has long been established. 
This association is not limited only to NAFLD. The 
practise of using lactulose for the treatment of hepatic 
encephalopathy suggests the involvement of gut flora 
in the management of liver disease. The association 
between gut flora with hepatic disease is popularly 
known as gut-liver axis. The understanding of the 
gut-liver axis will provide new opportunities for the 
management or even prevention of NAFLD.11,15
There are emerging evidence about the association 
between intestinal bacterial and fatty liver. The 
relationship between intestinal flora and alcoholic fatty 
liver disease has long been elaborated. When ethanol-
fed rats are given neomycin (to partially decontaminate 
the gut) or polymixin (to bind lipopolysaccharide/
LPS) or lactobacillus (to modify intestinal flora), they 
are protected from alcohol-induced liver damage. 
This protective effect is the result of reduced hepatic 
exposure to intestinal products, such as LPS, that 
induce the release of TNF-α from hepatic macrophage. 
As previously explained, TNF-α is the cytokine that 
promote cell death in the liver.14
It is logical to assume that similar effect of 
intestinal flora and NAFLD also exist, since TNF-α 
is also the key mediator in this disease. Currently 
there are two mechanisms by which intestinal flora 
may increase hepatic oxidative stress. The first 
one is increased endogenous ethanol production, 
and the second is direct activation of inflammatory 
cytokines in luminal epithelial cells, non-parenchymal 
liver cells (macrophages), or both via release of 
lipopolysaccharide (LPS). Both ethanol and bacterial 
LPS can activate TNF-α production in Kupffer cells 
and thus induce hepatic inflammation, oxidative stress 
and fibrosis.14,16
The role of endogenous ethanol production in 
NAFLD was initially studied in experiments with 
mice. The administration of neomycin significantly 
reduces endogenous ethanol production. This finding 
demonstrate a direct link between intestinal bacteria 
with ethanol production, and suggest that treatment of 
bacterial overgrowth might reduce the harmful effect 
of endogenous ethanol in NAFLD.14
While human experiment on this particular topic is 
still limited, one study noteworthy to know is a study 
by Wigg et al.17 According to this study, patients with 
NASH have a higher prevalence of small intestinal 
bacterial overgrowth. Small intestinal bacterial 
overgrowth was present in 50% of patients with NASH 
and 22% of control subjects (p = 0.048). Mean TNF-α 
levels in NASH patients and control subjects were 14.2 
and 7.5 pg/mL, respectively (p = 0.001).The level of 
endotoxin and intestinal permeability were similar in 
the two groups. This finding further supported the role 
of bacterial overgrowth in NAFLD, however failed 
to demonstrate a statistically significant correlation 
between TNF-α and endotoxin levels. Nevertheless, 
since it is a small scale study, the result need to be 
intepreted with cautious and future study with larger 
sample would hopefully provide valuable information 
concerning this topic.17





LPS: lipopolysaccharide; NASH: non-alcoholic steatohepatitis
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy106
Alvin Nursalim, Irsan Hasan
PROBIOTICS IN NAFLD
As intestinal bacteria plays a significant role in 
NAFLD, one obvious way to control the development 
of NAFLD is by manipulation of the intestinal bacteria. 
Currently, the manipulation of intestinal bacteria 
can be done by the administration of antibiotics and 
probiotics. Antibiotics seems a logical choice since 
this agent can decontaminate intestinal bacteria. The 
efficacy of antibiotics has been proven in a mice model. 
The administration of metronidazole and tetracycline 
reduced hepatic injury as shown by the decreased 
hepatic aminotransferase. However, long term use 
of antibiotics may cause bacterial resistance. Not to 
mention the side effects when these antibiotics are 
taken in long term.14,18
Competitive inhibiton of pathogens by probiotics 
alters their inflammatory effects in intestinal bacterial 
overgrowth. The beneficial effects of probiotic 
administration in NAFLD have been documented in 
multiple animal studies. According to Ma et al, the 
adminsitration of probiotic improved insulin resistance 
and steatosis in mice with diet-induced steatosis.19 Xu 
et al performed a study on a rat model of NAFLD and 
they also documented the beneficial effect of probiotic 
in reducing hepatic fat accumulation.20
Li et al also concluded that the administration of 
probiotic named VSL#3 (mixture of bifidobacteria, 
lactobacilli and stretococcus thermophilus) significantly 
reduced liver inflammation and slightly reduced 
hepatic steatosis. VSL#3 also decreased the DNA 
binding activity of nuclear factor κB (NF-κB), the 
target of IKKβ, another TNF-regulated enzyme that 
causes insulin resistance.21 Esposito et al, also found 
that VSL#3 reduced the level of TNF-α in NAFLD 
rats.22 All these animal studies agrees that probiotics 
are beneficial for NAFLD. Probiotics reduced hepatic 
inflammation, reduced hepatic steatosis and improved 
insulin resistance.
There are multiple pathways by which probiotics 
alter the progression of NAFLD. Probiotic may 
eradicate directly the pathogenic bacteria in the 
intestine. Probiotic also reduces bacteria ethanol 
production and reduces the inflammatory effect of 
intestinal bacteria through alteration in cytokine 
signaling (Figure 2).14,23
The beneficial effect of probiotic in other digestive 
disease like diarrheal and inflammatory disease has 
been studied in many human trials.11 However from 
recent literature searching, there is still limited clinical 
trial evaluating probiotic treatment involving human 
subject with NAFLD. A result from one pilot study 
seems promising though. Aller et al documented 
that a tablet containing 500 million of lactobacillus 
bulgaricus and Streptococcus thermophilus improved 
Figure 2. Probiotics role in the treatment of non-alcoholic fatty liver disease through its effect on 
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liver aminotransferase levels in patients with NAFLD.24 
Table 1 summarizes existing studies on animal and 
human subject concerning the role of probiotic in 
NAFLD.
Along with the progress of our knowledge about 
NAFLD, new treatments targeted at certain level of the 
disease would emerge. Lifestyle modification remains 
the first line treatment for NAFLD. In recent years, 
some potential NAFLD treatments have been the topic 
of discussion and study, one of which is probiotic. 
Not only probiotic is inexpensive, it is also safe and 
widely available, so the administration of this agent 
for NAFLD holds a promising future. Based on the 
efficacy and safety profile of probiotics, it can be an 
option for NAFLD treatment. However, limited data 
on human use made it unwise to give a supportive 
recommendation from an evidence based perspective, 
but neither is it opposed.
Existing human trials are small scale trials with 
limited period of follow up, therefore larger clinical 
trial with longer follow up is  needed.24,25 There are 
some questions need to be addresed in future reasearch. 
First, the strain of probiotic bacteria that would be 
best for NAFLD treatment. Second, the amount of 
probiotic needed to produce significant effect among 
NAFLD patients.
CONCLUSION
 As our understanding about the pathogenesis 
of NAFLD advances, new insight regarding potential 
treatment for this disease would ultimately emerge. 
There are accumulating evidences that probiotic is 
a new approach in the treatment of NAFLD. The 
characteristic of probiotic is suitable for NAFLD 
treatment. All existing studies provide favorable result 
for the use of probiotic in NAFLD treatment.
However up to this time, there is still limited data 
on the use of probiotic for NAFLD on human. So, 
evidence-based recommendation cannot be decided 
yet. This review hopefully provides new information 
and triggers upcoming study that would eventually 
become solid evidence for wide implementation in 
clinical practice.
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